A Study of the Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours

Solid Tumor Clinical Trial

Official title:

A Phase 1b Dose-escalation Study to Evaluate the Safety and Tolerability of the Addition of the Aminopeptidase Inhibitor CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00737555
• Other study ID #: CHR-2797-003
• Secondary ID: EudraCT# 2006-00
• Status: Completed
• Phase: Phase 1
• First received: August 18, 2008
• Last updated: February 14, 2012
• Start date: August 2006
• Est. completion date: March 2008

Study information

• Verified date: February 2012
• Source: Chroma Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
• Study type: Interventional

Clinical Trial Summary

The treatment of cancer often involves the use of more than one drug at the same time. In this study, patients are treated with the already marketed drug paclitaxel (administered every 3 weeks by infusion)and with the investigational drug CHR-2797 (given orally, once daily). The purpose of this study is to evaluate if it is safe to administer these two drugs together, and how well the combination is tolerated by patients. The first patients will receive a 90mg dose of CHR-2797; doses will be increased in subsequent patients, as long as they are adequately tolerated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: March 2008
• Est. primary completion date: March 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed, informed consent.

• Age > 18 years

• Histologically or cytologically documented locally advanced or metastatic solid tumour refractory to standard therapy or for which no standard therapy exists.

• Patients should have recovered from the acute adverse effects of prior therapies (excluding alopecia).

• Adequate bone marrow, hepatic and renal function including the following:

• Hb > 9g/dl (transfusion independent) or >10g/dl (transfusion permitted), absolute neutrophil count > 1.5 x 109/L, platelets = 100 x 109/L;

• Total bilirubin = 1.5 x upper normal limit;

• AST (SGOT), ALT (SGPT) = 2.5 x upper normal limit

• Creatinine =1.5 x upper normal limit.

• Performance status (PS) = 2 (ECOG scale).

• Estimated life-expectancy greater than 3 months.

• Female patients with reproductive potential must have a negative serum pregnancy test within 7 days prior to start of trial. Both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months after discontinuation of treatment.

Exclusion Criteria:

• Anti-cancer therapy including chemotherapy, radiotherapy, endocrine therapy, immunotherapy or use of other investigational agents within the 4 weeks prior to first dose of medication in this trial or within a longer period, depending on the defined characteristics of the agent e.g. 6 weeks for nitrosurea or mitomycin. Bisphosphonates for bone disease are permitted provided the doses are stable before and during the trial.

• Co-existing active infection or serious concurrent illness.

• Significant cardiovascular disease as defined by:

• history of congestive heart failure requiring therapy;

• history of unstable angina pectoris or myocardial infarction up to 6 months prior to trial entry;

• presence of severe valvular heart disease;

• presence of a ventricular arrhythmia requiring treatment.

• Any co-existing medical condition that in the investigator's judgement will

• substantially increase the risk associated with the patient's participation in the study.

• Psychiatric disorders or altered mental status precluding understanding of the

• informed consent process and/or completion of the necessary studies.

• Gastrointestinal disorders that may interfere with absorption of the study drug.

• Persistent grade II or greater toxicity from any cause.

• Patients with known brain tumours or metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurological dysfunction that would confound the evaluation of neurologic and other adverse events.

• More than 4 prior chemotherapy regimens.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Solid Tumor

Intervention

Drug:
• CHR-2797
Oral once daily administration of capsules of CHR-2797, to determine safety and tolerability in patients being treated with paclitaxel infusion every 3 weeks for up to 18 weeks.

Locations

Country	Name	City	State
Netherlands	UMC St Radboud	Nijmegen
Netherlands	Erasmus MC University Medical Centre- Location Centrum	Rotterdam

Sponsors (1)

Lead Sponsor	Collaborator
Chroma Therapeutics

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the safety, tolerability, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of CHR-2797 when administered in combination with paclitaxel.		18 weeks	Yes
Secondary	To evaluate the pharmacokinetic profile of the combination of CHR-2797 and paclitaxel and identify any pharmacokinetic interaction between the 2 agents.		After 1st and 2nd infusion of paclitaxel	Yes
Secondary	To determine response and response duration, time to progressive disease or treatment failure during combination therapy and in those patients who continued beyond 18 weeks on monotherapy with CHR-2797.		Maximum duration of patient treatment ( combination followed by monotherapy) was 9 months	No

External Links

•   British Journal of Cancer 103, 1362-1368 (26 October 2010)
•   EORTC-NCI-AACR Symposium, October 2008